Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11377840 | 0.84 | LMNA (0.32) | LMNAALDH1A1TSHR | |
| SCHEMBL4335654 | 0.81 | — | — | |
| SCHEMBL18394630 | 0.79 | — | — | |
| SCHEMBL2294883 | 0.76 | ALDH1A1 (0.33) | LMNAALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL11629040 | 0.74 | LMNA (0.32) | LMNAALDH1A1TSHR | |
| SCHEMBL31282806 | 0.73 | HCAR2 (0.55) | ALDH1A1TSHR | |
| SCHEMBL29637404 | 0.73 | EGLN1 (0.41) | LMNATSHR | |
| SCHEMBL29637431 | 0.73 | HCAR2 (0.55) | ALDH1A1TSHR | |
| SCHEMBL28592054 | 0.72 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL30307070 | 0.72 | TSHR (0.38) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070276-A | Prodrugs of xanomeline, prodrugs of trospium chloride and methods of using the same | 人类生物科学股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-114423740-A | Pyrazole derivatives for controlling arthropods | 拜耳动物保健有限责任公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-1501797-B1 | 3-(SUBSTITUTED AMINO)-1H-INDOLE-2-CARBOXYLIC ACID ESTER AND 3-(SUBSTITUTED AMINO)-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID ESTER DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMA INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080132481-A1 | INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMACEUTICALS INC. | 2008-06-05 | — | — | US | disclosed |
| EP-1834947-A2 | 3-substituted amino-1H-indole-2-carboxylic acid and 3-substituted amino-benzo[B]thiophene-2carboxylic acid derivatives as interleukin-4 gene expression inhibitors | Aventis Pharmaceuticals, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1501796-B1 | 3-(PYRIDINYL-AMINO)-1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMA INC (US) | 2007-05-09 | — | — | EP | disclosed |
| US-7169925-B2 | Indole derivatives as interleukin-4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1501796-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1501797-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040010029-A1 | Indole derivatives as interleukin -4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-01-15 | — | — | US | disclosed |
| US-20040006123-A1 | Interleukin-4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2003091215-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO’ B! THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERIEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003091214-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO | AVENTIS PHARMACEUTICALS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010029-A1 | Indole derivatives as interleukin -4 gene expression inhibitors | IL4, IL4I1, STAT4 | LMNA 4813/4885ALDH1A1 1468/4885TSHR 1861/4885 |
| US-20040006123-A1 | Interleukin-4 gene expression inhibitors | IL4, STAT4, BCL6 | LMNA 4805/4885ALDH1A1 1578/4885TSHR 1105/4885 |
| US-20080132481-A1 | INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | IL4, STAT4, STAT6 | LMNA 4793/4885ALDH1A1 1900/4885TSHR 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.